Replay available

Syros Pharmaceuticals, Inc. (SYRS) Q4 2023 Earnings Call

Syros Pharmaceuticals, Inc. (NASDAQ: SYRS) Q4 2023 earnings conference call, held 2024-03-27. Replay captured from the company's public earnings webcast.

Wed, March 27, 2024 at 8:30 AMendedReplay
Syros Pharmaceuticals, Inc. (SYRS) Q4 2023 Earnings Call

Investor webinar replay

Latest press releases

Companies on this event

Featured Presenters

Karen Hunadi

Director of Investor Relations and Corporate Communications

Phil Nadeau

Analyst, TD Cowen

Dr. David Roth

Chief Medical Officer

Jason Butler

Analyst, Citizens JMP

Conley Chee

Chief Executive Officer

Jason Haas

Chief Financial Officer

Replay transcript excerpt

quarter and full year 2023 financial results conference call. At this time, all participants are in a listen-only mode. This call is being webcast live on the Investors and Media section of Cirrus website at www.cirrus.com. Please be advised that today's call is being recorded. At this time, I would like to turn the call over to Karen Hunadi, Director of Investor Relations and Corporate Communications at Cirrus. Thank you. This morning, we issued a press release announcing our fourth quarter and full year 2023 financial results. The full release is available on the investor and media section of the Cirrus's website at www.cirrus.com. We will begin the call with prepared remarks by Conley Chee, our Chief Executive Officer, Dr. David Roth, our Chief Medical Officer, and Jason Haas, our Chief Financial Officer. We will then open the call for questions. Kristen Stevens, our Chief Development Officer, is also here on the call and will be available for Q&A. Before we begin, I would like to remind everyone that the statements we make on this conference call will include forward-looking statements. Actual events or results could differ materially from those expressed or implied by any forward-looking statements as a result of various risks, uncertainties, and other factors. including those set forth in the risk factors section of our annual report on Form 10-K that we filed this morning, and any other filings that we may make with the SEC in the future. Any forward-looking statements represent our views only as of today and should not be relied upon as representing our views as of any subsequent date. We specifically disclaim any obligation to update or revise any forward-looking statements. With that, I would now like to turn the call over to Conley. Conley? Thank you, Kare...

More from Syros Pharmaceuticals, Inc.